Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6454723 | 0.83 | P2RX7 (0.62) | P2RX7GRM5HSP90AA1NOS3NOS2 | |
| SCHEMBL6451427 | 0.80 | P2RX7 (0.30) | P2RX7 | |
| SCHEMBL2240378 | 0.69 | P2RX7 (0.51) | P2RX7GRM5HSP90AA1NOS3NOS2 | |
| SCHEMBL18414338 | 0.68 | P2RX7 (0.50) | P2RX7GRM5HSP90AA1NOS3NOS2 | |
| SCHEMBL1580850 | 0.68 | P2RX7 (0.50) | P2RX7GRM5HSP90AA1NOS3NOS2 | |
| SCHEMBL6454385 | 0.67 | P2RX7 (0.47) | P2RX7GRM5HSP90AA1 | |
| SCHEMBL9792890 | 0.66 | P2RX7 (0.39) | P2RX7HSP90AA1 | |
| SCHEMBL23865131 | 0.65 | NOS3 (0.39) | P2RX7NOS3NOS2 | |
| SCHEMBL29843729 | 0.64 | P2RX7 (0.53) | P2RX7GRM5HSP90AA1NOS3NOS2 | |
| SCHEMBL1443336 | 0.64 | P2RX7 (0.53) | P2RX7GRM5HSP90AA1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | P2RX7 1072/4885GRM5 4040/4885HSP90AA1 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.